Record-Breaking Life Sciences Fund Launched: Blackstone Completes Final Close at $6.3 Billion
Blackstone Life Sciences Fund VI Closes
Blackstone, the world's largest alternative investment asset manager, has established the largest-ever private equity fund in the life sciences sector.
On March 31, Blackstone announced that its “Life Sciences Fund VI” had completed fundraising at a total of $6.3 billion (approximately KRW 9.6031 trillion). This marks a roughly 40% increase in scale compared to the previous Fund V. The company explained that due to strong investor demand, the fund reached its hard cap and closed oversubscribed.
Nicholas Galakatos, Global Head of Blackstone Life Sciences, stated, “Blackstone has successfully enabled a total of 34 drug and medical device approvals through partnerships with leading global companies. These achievements demonstrate our capability to effectively deliver essential products to patients, based on our collaboration with corporations.”
In 2018, Blackstone launched its dedicated platform, Blackstone Life Sciences, to invest in key companies and products in the life sciences field. As of the fourth quarter of 2025, it managed approximately $15 billion in assets under management (AUM). Since its establishment, the firm has invested in innovative projects, supporting the development of more than 215 pharmaceutical products to date.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Over the past 12 months, Blackstone has executed new investments totaling around $2 billion. Major investment cases include: ▲ Funding research and development related to sacituzumab tirumotecan (sac-TMT) with Merck ▲ Co-investment in an acute myeloid leukemia treatment ▲ A $400 million strategic investment with Teva for the development of duvakitug ▲ A $2 billion strategic financial partnership with Alnylam to accelerate the development of RNAi therapeutics ▲ Support for Anthos Therapeutics in its acquisition by Novartis.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.